News
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback